Literature DB >> 2986670

Development of polyneuropathy during thalidomide therapy.

C H Wulff, H Høyer, G Asboe-Hansen, H Brodthagen.   

Abstract

Seven patients with prurigo nodularis and one with aphthous stomatitis were given 40-115 g of thalidomide for 1 to 6 years. They all developed a predominantly sensory peripheral neuropathy mainly involving the lower limbs. Five patients had an unpleasant tight feeling around the feet. Nerve conduction studies showed small sensory action potentials from the lower limbs with normal or only mild slowing of sensory conduction velocity indicating an axonal neuropathy. The dermatological disorder improved dramatically in all, but treatment had to be discontinued because of the severe side-effects. Thalidomide, if used, should be given only over a short period because of its neurotoxic effect.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2986670     DOI: 10.1111/j.1365-2133.1985.tb02323.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  16 in total

1.  Aphthous ulcers in HIV-infected patients: treatment with thalidomide.

Authors:  S Strazzi; C Lebbe; C Geoffray; G Ablon; P Morel; O Verola; J M Molina
Journal:  Genitourin Med       Date:  1992-12

2.  Use of thalidomide in leprosy.

Authors:  M F Waters
Journal:  BMJ       Date:  1991-08-24

3.  Use of thalidomide in leprosy.

Authors:  C L Crawford
Journal:  BMJ       Date:  1991-06-29

4.  Safety of thalidomide.

Authors:  C L Crawford
Journal:  BMJ       Date:  1994-05-28

5.  Thalidomide-induced neuropathy and genetic differences in drug metabolism.

Authors:  C C Harland; G B Steventon; J R Marsden
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  Therapeutic potential for cytokine antagonists: Thalidomide and pentoxifylline in Hansen's disease.

Authors:  T C Peterson
Journal:  Can J Infect Dis       Date:  1995-01

Review 7.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

8.  Treatment of Behçet's disease with thalidomide.

Authors:  M H Hamza
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

Review 9.  Thalidomide: rationale for renewed use in immunological disorders.

Authors:  U Schuler; G Ehninger
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

10.  Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood.

Authors:  R Neubert; A C Nogueira; D Neubert
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.